Heart Valve Replacement (Transcatheter)
Transcatheter valve technology represents a less invasive means for treating heart valve disease and is designed to allow physicians to deliver replacement valves via a catheter through the body's cardiovascular system, thus eliminating the need to open the chest.
CoreValve Evolut R Transcatheter Aortic Valve
The CoreValve® Evolut® R Transcatheter Aortic Valve (TAVR) system was built on the proven foundation of the CoreValve platform. It was designed specifically to meet the clinical needs of patients with severe aortic stenosis at extreme or high risk for surgical valve replacement.
The Evolut R system provides control during deployment for accurate positioning with the ability to recapture and reposition the valve. It is the only system indicated down to 5.0mm vessel diameter—that's the lowest profile for all valve sizes in the market today–and treats an annulus range from 17*/18-26 mm.
Deliberate design improvements to the Evolut R valve contribute to an enhanced sealing with a more conformable frame, resulting in exceptional hemodynamics.
For more information, visit EvolutR.com.
*Measurement for TAV–in–SAV only.
Melody Transcatheter Pulmonary Valve Therapy
A Less Invasive Approach to Restore Pulmonary Valve Function
With Melody® TPV Therapy, children and adults with dysfunctional pulmonary valve conduits have a proven treatment option designed to restore pulmonary valve function and delay the need for surgical intervention. Thousands of patients from around the world have benefited from this therapy.
The Melody valve is specifically designed to treat Right Ventricular Outflow Tract (RVOT) valve dysfunction. Comprised of a bovine jugular vein (BJV) valve sutured within a platinum iridium frame, the Melody valve has natural venous valve leaflets which open and close under minimal pressure for optimal hemodynamics. Deep coaptation of the leaflets provides valve competency across a range of conduit sizes and geometries. The Melody Valve is delivered via the Ensemble® Delivery System, which utilizes balloon-in-balloon (BIB) technology for controlled valve deployment.
Data from the US IDE Study showed strong valve performance, with approximately 98 percent of patients free from conduit reoperation at two years post-implant and 91 percent of patients free from conduit reoperation at five years post-implant.
For more information, visit www.medtronic.com/melody.